Meat and fish consumption and risk of lung cancer: A case-control study in Galicia, Spain.

Diet is one of the elements that may influence the development of lung cancer. To ascertain the relationship between meat and fish consumption and the appearance of this disease, a case-control study was conducted on a population in Galicia (NW Spain), with a sample of 295 cases and 322 controls. All cases had histologic confirmation, and controls were individuals who were attending the hospital to undergo trivial surgery. All subjects were over 35, and sampling was based on sex frequency. Frequent consumption of meat seemed to have a protective effect, with an OR of 0.24 (95% CI 0.11-0.50), an effect that was maintained for pork consumption (OR 0.35; 95% CI 0.18-0.67). In contrast, consumption of fish showed an association with lung cancer, with an OR of 1.67 (95% CI 0.99-2.81), an association that extended to both white (OR 1.61 95% CI 0.93-2.79) and blue fish (OR 2.03 95% CI 1.23-3.34). Consumption of meat seems to reduce the risk of lung cancer, whereas consumption of fish could exert an influence by increasing the risk of this disease.

Adecuación de la prescripción de hipolipemiantes y riesgocardiovascular en pacientes con hipercolesterolemia / Appropriateness of lipid-lowering treatment and cardiovascular risk in patients with hypercholesterolemia

Objetivo: Valorar la adecuación en la prescripción de hipolipemiantes y conocer diversas características clinicoepidemiológicas de los pacientes con hipercolesterolemia. Método: Población objeto de estudio: todos los pacientes con hipercolesterolemia pertenecientes a tres centros de salud urbanos. Muestreo por conglomerados monoetápico (n = 724). Estudio descriptivo con dos tipos de diseño: longitudinal retrospectivo y transversal. Para el primero de los diseños se utilizaron las nuevas tablas de riesgo cardiovascular (RCV) de Sheffield; para el segundo, las de Framingham por categorías (Grundy). Resultados: Entre los pacientes en prevención primaria, hubo una adecuación en la prescripción en un 44,2% de los pacientes. Tienen actualmente un riesgo absoluto elevado (≥ 20% a 10 años) un 8,9% (1,1) de nuestros pacientes de 30 a 74 años de edad en (..) (AU)

Objective: To assess the appropriateness of lipid-lowering treatment and to determine the clinical and epidemiological characteristics of patients with hypercholesterolemia. Method: The study population comprised all the patients diagnosed with hypercholesterolemia in three urban health centres. A sample of 724 patients was obtaind through a one-stage conglomerate method. A descriptive study was performed with two types of designs: retrospective and longitudinal, and cross-sectional. For the first we used the new Sheffield tables for cardiovascular risk; for the second, the Framingham categorical tables (Grundy). Results: Among patients in primary prevention, prescription of lipid-lowering therapy was appropiate in 44.2%. A total of 8.9% (SE = 1.1) of the patients aged 30-74 years in primary prevention had a high absolute risk (≥ 20% over 10 years). Six percent (0.8) had a high relativd risk and 18.1% (2.0) had a moderately above-average risk. Conclusions: More than the half of the patients were prescribed lipid-lowering treatment that was not indicated by risk tables. The current cardiovascular risk of our patients is satisfactory (AU)

[Appropriateness of lipid-lowering treatment and cardiovascular risk in patients with hypercholesterolemia]. / Adecuación de la prescripción de hipolipemiantes y riesgo cardiovascular en pacientes con hipercolesterolemia.

OBJECTIVE: To assess the appropriateness of lipid-lowering treatment and to determine the clinical and epidemiological characteristics of patients with hypercholesterolemia. METHOD: The study population comprised all the patients diagnosed with hypercholesterolemia in three urban health centres. A sample of 724 patients was obtained through a one-stage conglomerate method. A descriptive study was performed with two types of designs: retrospective and longitudinal, and cross-sectional. For the first we used the new Sheffield tables for cardiovascular risk; for the second, the Framingham categorical tables (Grundy). RESULTS: Among patients in primary prevention, prescription of lipid-lowering therapy was appropriate in 44.2%. A total of 8.9% (SE = 1.1) of the patients aged 30-74 years in primary prevention had a high absolute risk (>/= 20% over 10 years). Six percent (0.8) had a high relative risk and 18.1% (2.0) had a moderately above-average risk. CONCLUSIONS: More than the half of the patients were prescribed lipid-lowering treatment that was not indicated by risk tables. The current cardiovascular risk of our patients is satisfactory.